<DOC>
	<DOCNO>NCT00772122</DOCNO>
	<brief_summary>In order investigate effectiveness G-CSF prevent embryo demise , investigator administer cytokine woman recurrent miscarriage randomize control study compare woman treat placebo . Sixty eight woman unexplained primary recurrent miscarriage , least four consecutive abortion negative clinical investigation select study . Patients randomly treat G-CSF , start 6th day ovulation , placebo .</brief_summary>
	<brief_title>Use G-CSF Treatment Unexplained Recurrent Miscarriage</brief_title>
	<detailed_description>The patient unexplained primary ( previous successful pregnancy ) recurrent miscarriage ( RM ) refer Hungaria Center Endocrinology Reproductive Medicine January 2000 January 2007 consider eligible study . The patient fulfil follow inclusion criterion : woman 's age le 39 year , 4 previous abortion , failure previous treatment RM ( immunoglobulin infusion ) , negative know cause RM The study review approve Institutional Review Board , clinical study conduct accord Italian law Declaration Helsinki Medical Research involve Human Subjects . A sample size calculation show total 32 patient per group need order difference 33 % two group p &lt; 0.005 beta &gt; 0.80 A total 72 patient consider eligible study , 68 agree participate , sign informed consent form . All patient inform eventual potential risk treatment mother foetus , lack information developmental toxicity G-CSF . The patient randomize mean computer generate randomization number sequence . All patient inform therapy give write informed consent . They randomly assign two arm study , one G-CSF treatment placebo administration ; patient blind treatment assign . The G-CSF group 35 woman , underwent daily sub-cutaneous administration filgrastim ( Neupogen , Dompe ' , Italy ) , recombinant G-CSF , dosage 1 microgram ( 100000 IU ) /kg/day 6th day ovulation till occurrence menstruation end 9th week gestation . The placebo group consist 33 subject , give treatment subcutaneous saline solution dosage 0.2 ml daily , also case , 6th day ovulation till recurrence menstrual loss end 9th week . Primary outcome consider pregnancy outcome .</detailed_description>
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<mesh_term>Abortion , Habitual</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>four previous consecutive abortion , fail previous treatment intravenous immunoglobulin negative clinical investigation recurrent miscarriage last abortion fetal karyotype show chromosomal abnormality previous successful pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Recurrent Miscarriage</keyword>
	<keyword>G-CSF</keyword>
	<keyword>pregnancy outcome</keyword>
	<keyword>pregnancy outcome pregnancy treat G-CSF</keyword>
	<keyword>treatment recurrent miscarriage</keyword>
</DOC>